The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F16%3AN0000168" target="_blank" >RIV/00064173:_____/16:N0000168 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/16:43911860 RIV/00216208:11110/16:10327713
Result on the web
<a href="http://dx.doi.org/10.1016/j.diabres.2016.06.020" target="_blank" >http://dx.doi.org/10.1016/j.diabres.2016.06.020</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.diabres.2016.06.020" target="_blank" >10.1016/j.diabres.2016.06.020</a>
Alternative languages
Result language
angličtina
Original language name
The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus
Original language description
Aim: To assess intraindividually the effects of DPP-IV inhibition on the subpopulations of immune cells in type 2 diabetes mellitus (DM2) patients during the course of treatment with sitagliptin. Methods: In this open label non-randomized observational study with a control group DM2 patients were examined before the initiation of the DPP-IV inhibitor administration (sitagliptin 100mg once daily) and then after 4weeks and 12months. Inhibition of the blood plasma DPP-IV enzymatic activity was determined by a chromogenic assay, the immunophenotyping of the blood cell subpopulations was performed using flow cytometry and blood plasma cytokine concentrations were quantified using an array-based multiplex ELISA. All parameters were evaluated in relation to the entry values in individual patients. Results: The blood plasma DPP-IV enzymatic activity was effectively inhibited during the sitagliptin treatment. A significant decrease of the proportion of Treg cells (to 86+-31% (median+-SD) of entry values, p=0.001) and an increase of Th1 cells (to 120+-103% (median+-SD) of entry values, p=0.004) were observed after 4weeks but not after one year of the sitagliptin treatment. No changes were observed in the ratio of CD4(+)/CD8(+) cells, in the quantity of NK and Th2 cells and blood plasma cytokine levels. Conclusions: Sitagliptin treatment may cause temporary changes of the proportion of lymphocyte subpopulations in patients with DM2. The consequent deregulation of the immune system should be considered as a possible cause of the eventual side effects of long term DPP-IV inhibition.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FB - Endocrinology, diabetology, metabolism, nutrition
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT12407" target="_blank" >NT12407: The impact of DPP-4 inhibitor therapy on immunity functions in patients with type 2 diabetes mellitus</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diabetes Research and Clinical Practice
ISSN
0168-8227
e-ISSN
—
Volume of the periodical
118
Issue of the periodical within the volume
August
Country of publishing house
IE - IRELAND
Number of pages
10
Pages from-to
183-192
UT code for WoS article
000381646800026
EID of the result in the Scopus database
2-s2.0-84977263014